The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.
Khaldoun Almhanna
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Millennium
Jordi Rodon Ahnert
No relevant relationships to disclose
Cristina Cruz
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
JungAh Jung
Employment or Leadership Position - Millennium
Adedigbo Fasanmade
Employment or Leadership Position - Millennium
Tim Wyant
Employment or Leadership Position - Millennium
Thea Kalebic
Employment or Leadership Position - Millennium
Stock Ownership - Takeda